Filana Therapeutics receives Nasdaq notice on minimum bid shortfall
Nasdaq notified Filana Therapeutics that its common stock failed the $1.00 minimum bid price for 30 consecutive business days under Listing Rule 5550(a)(2). The company has until March 16, 2027 to regain compliance by achieving a $1…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.